drugset / Trial / NCT05578820
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of different doses and administration regimens of Stimotimagene copolymerplasmid in patients with histologically confirmed diagnosis of solid tumor and/or its metastases.
Timeline
- Start
- 2022-01-01
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Stimotimagene copolymerplasmid | Unknown | 20 ug | Other |
| Subject | Stimotimagene copolymerplasmid | Unknown | 40 ug | Other |
| Background | Ganciclovir | Small molecule | — | Intravenous |